Cardiovascular and Metabolic Models and Studies

Charles River offers a comprehensive cardiovascular and metabolic disease drug discovery service portfolio, including innovative target identification and validation platforms, complex in vitro assays, in vivo cardiovascular and metabolic models, and a strong chemistry and disease biology foundation, all of which assist in translating basic research to clinical reality.

Our metabolic laboratory scientists can help biopharmaceutical companies engaged in cardiovascular and metabolic disease drug discovery research advance their program. We provide a number of in vivo pharmacology cardiovascular and metabolic models and in vitro discovery models including:

Combining our well-characterized in vivo and in vitro cardiovascular and metabolic models and broad suite of translational biomarkers provides our partners the flexibility they need to demonstrate the therapeutic efficacy of their compounds.

Scientists working in pharmaceutical formulation laboratory designed to eliminate cross-contamination and suitable for the preparation of preclinical dosing formulations of any batch size

Pharmaceutical Formulation Development
A formulator should be an integral part of your development team as the physicochemical characterization and varied formulation techniques have become increasingly more complex.
Learn more about our formulation development capabilities

Assess Clinically Relevant Endpoints in Metabolic Models

Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic properties, appropriate preclinical safety profiles and data packages supporting on-target effects that can be assessed in multiple animal models. Our Discovery Services group is made up of skilled technicians and scientists with decades of experience in big pharma and biotech who collectively have seen hundreds of programs move through the discovery process. We can guide your research towards a wide array of potential analytical endpoints, including:

Simply put, we offer a suite of services as a metabolic disease CRO, including a range of cardiovascular and metabolic models, to get you a go/no-go answer on your Cardiovascular and Metabolic drug discovery programs.

Accelerate Drug Discovery Using In Vitro Assays with Disease-relevant Human Primary Cells

In addition to animal models of metabolic disease and cardiovascular disease, in vitro assays using disease-relevant cells can provide the earliest prediction of how a compound will translate to clinic. Our Discovery Services group has established a wide range of in vitro assays in diverse disease-relevant cell types to study metabolic and cardiovascular diseases. In addition, custom-generated assay formats can be developed to meet your study needs.

Key Capacities and Expertise for Metabolic & Cardiovascular Diseases:

  • Target discovery and validation: Combining sophisticated genetic manipulation techniques with complex cell-based assays, including those developed in stem cells, primary human or rodent cells, and patient-derived cells.
  • Disease-relevant cellular assays: Medium to high throughput assays with readouts such as high-content imaging, real-time cellular bioenergetics, and Seahorse analysis using human primary or iPSC derived cells.
  • Biology assays are available for screening and profiling campaigns across diverse modalities: small molecules, biotherapeutics (e.g. antibody incl. multi-specific, nanobodies, peptides, proteins, PROTAC, LYTAC), antisense oligonucleotides, mRNA, cell therapy, etc.
  • Biomarker discovery and development: Multiple targeted assays and omics technologies, including lipidomics and metabolomics, from discovery to clinical sample analysis.

Which cardiovascular or metabolic model is right for your program?

Discuss Your Cv/Met Program